Replies to post #3245 on Spectrum Pharmaceutecals Inc (SPPI)

[dcaf7]

I consider it slightly positive. Spectrum merged with profitable company with 6 drugs approved. Most important one is Indocin and it faces generic competition. I assume plan is that Rolvedon will replace Indocin revenue. CVR is Contingent Value Right. Consider it as a bonus for achievement of certain milestone. In our case, SPPI shareholders will receive a few more shares of ASRT if Rolvedon sales exceed $175 million during the calendar year ending December 31, 2024, and again a few more shares on revenue of $225 million during the calendar year ending December 31, 2025.